Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

INmune Bio Inc

INMB
Current price
7.32 USD +0.01 USD (+0.14%)
Last closed 7.30 USD
ISIN US45782T1051
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 167 849 792 USD
Yield for 12 month -31.11 %
1Y
3Y
5Y
10Y
15Y
INMB
21.11.2021 - 28.11.2021

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Address: 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

23.40 USD

P/E ratio

Dividend Yield

Current Year

+14 000 USD

Last Year

+155 000 USD

Current Quarter

Last Quarter

Current Year

+14 000 USD

Last Year

+155 000 USD

Current Quarter

Last Quarter

Key Figures INMB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA
Operating Margin TTM -304 535.72 %
Price to Earnings
Return On Assets TTM -55.19 %
PEG Ratio
Return On Equity TTM -119.83 %
Wall Street Target Price 23.40 USD
Revenue TTM 14 000 USD
Book Value 1.44 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM 14 000 USD
Earnings per share -2.11 USD
Diluted Eps TTM -2.11 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics INMB

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History INMB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor
Payout Ratio
Last Split Date

Stock Valuation INMB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 10 522.28
Price Sales TTM 11 989.27
Enterprise Value EBITDA -5.31
Price Book MRQ 5.23

Financials INMB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators INMB

For 52 weeks

4.32 USD 12.72 USD
50 Day MA 8.09 USD
Shares Short Prior Month 5 575 380
200 Day MA 6.76 USD
Short Ratio 23.33
Shares Short 6 060 191
Short Percent 32.85 %